Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab Beta with Induction Chemotherapy in High-Risk Neuroblastoma
NCT06485947Phase 1Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jan 2025
- Primary completion
- Jul 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Dinutuximab beta in neuroblastoma (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Incidence of Dose Limiting Toxicities at 50 days. Started Jan 2025; status: recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06485947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485947.